Immune-Calming drug shows promise for rare lung complication

NCT ID NCT04925375

First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether abatacept (Orencia) can improve lung disease in people with common variable immunodeficiency (CVID). About 38 children and adults will receive either the drug or a placebo for 6 months. The main goal is to see if lung damage on CT scans shrinks by at least 30%.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Abatacept (also known as Orencia), a drug that calms the immune system
What this could lead to
If it works, this could point toward a new treatment for a rare lung complication in people with common variable immunodeficiency, potentially improving breathing and quality of life.
What could go wrong
This is a small, early-phase trial with only 38 participants, so results may not apply to everyone. The drug also suppresses the immune system, which could increase infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMMON VARIABLE IMMUNODEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cincinnati Children's Hospital Medical Center

    RECRUITING

    Cincinnati, Ohio, 45229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Duke University Health System

    RECRUITING

    Durham, North Carolina, 27710, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Lahey Hospital and Medical Center

    RECRUITING

    Burlington, Massachusetts, 01805, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55902, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of South Florida

    RECRUITING

    Tampa, Florida, 33620, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.